Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Clinical trial NCT03779100 · SUSPENDED

Trial details

NCT number: NCT03779100
Sponsor: Shi Ming
Status: SUSPENDED
Phase: Phase 2
Study type: INTERVENTIONAL

Intrahepatic Cholangiocarcinoma

Start date: 2018-12-17
Primary completion: 2019-12-31
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.